drugset / Trial / NCT00080496

Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia

NCT00080496

Phase 3 Completed 430 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.

Timeline

Start
2003-07
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilastatin Small molecule
Subject IMIPENEM ANHYDROUS Small molecule
Subject Tigecycline Small molecule

Indications